US study assesses safety of artificial liver:
This article was originally published in Clinica
Executive Summary
VitaGen has begun a US clinical trial to evaluate the safety of its artificial liver. The extracorporeal liver assist device (ELAD) is designed to provide temporary hepatic replacement therapy for patients with fulminant hepatic failure until their own liver can regenerate itself or until a donor organ becomes available for transplant. During the study, patients with fulminant hepatic failure caused by drug, chemical, poison or viral causes and with no previous evidence of chronic liver disease will be treated with the ELAD artificial liver for up to 10 days, said La Jolla, California-based VitaGen.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.